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Abstract
Background: Peptides derived from endogenous antigens can bind to MHC class I molecules.
Those which bind with high affinity can invoke a CD8+ immune response, resulting in the
destruction of infected cells. Much work in immunoinformatics has involved the algorithmic
prediction of peptide binding affinity to various MHC-I alleles. A number of tools for MHC-I binding
prediction have been developed, many of which are available on the web.
Results: We hypothesize that peptides predicted by a number of tools are more likely to bind than
those predicted by just one tool, and that the likelihood of a particular peptide being a binder is
related to the number of tools that predict it, as well as the accuracy of those tools. To this end,
we have built and tested a heuristic-based method of making MHC-binding predictions by
combining the results from multiple tools. The predictive performance of each individual tool is first
ascertained. These performance data are used to derive weights such that the predictions of tools
with better accuracy are given greater credence. The combined tool was evaluated using ten-fold
cross-validation and was found to signicantly outperform the individual tools when a high specificity
threshold is used. It performs comparably well to the best-performing individual tools at lower
specificity thresholds. Finally, it also outperforms the combination of the tools resulting from linear
discriminant analysis.
Conclusion: A heuristic-based method of combining the results of the individual tools better
facilitates the scanning of large proteomes for potential epitopes, yielding more actual high-affinity
binders while reporting very few false positives.
Background
The major histocompatibility complex (MHC) is a set of
genes whose products play a crucial role in immune
response. Peptides derived from the proteasomal degrada-
tion of intracellular proteins are presented by MHC class I
molecules to cytotoxic T lymphocytes (CTL) [1-3], and
recognition of a non-self peptide by a CTL can result in the
destruction of an infected cell. Peptides that can complete
this pathway are called T cell epitopes.
Only 0.5% of peptides are estimated to bind to a given
MHC-I molecule, making this the most selective step in
the recognition of intracellular antigens [4,5]. Given the
large size of many viral and bacterial proteomes, it is pro-
hibitive in terms of time and money to test every possible
peptide for immunogenicity; thus, tools for the computa-
tional prediction of peptides that are likely to bind to a
given MHC-I allele are invaluable in facilitating the iden-
tification of T cell epitopes.
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Many tools for performing such predictions, of varying
quality, are available. We hypothesize that greater predic-
tive accuracy can be achieved by combining the predic-
tions from several of these tools rather than using just one
tool. Further, contributions from individual tools should
be related to their accuracy. To test this hypothesis, we
have built a prediction tool which assigns a "combined
score" to each peptide in a given protein by taking into
account the predictive performance of each tool, and the
score given by that same tool to a given peptide. We also
compare our technique with combined predictions made
using linear discriminant analysis, a standard statistical
method for combining variables to distinguish two
groups (in this case, "binder" and "non-binder"). In this
paper, the acronym "HBM" will refer to our heuristic-
based method and "LDA" will refer to the predictor built
using linear discriminant analysis.
Results and discussion
Performance of the individual tools
Table 1 shows the ability of each individual tool to dis-
crimine between the binders and nonbinders to HLA-
A*0201 derived from the community binding database
[6]. As we are interested in good sensitivity at high specif-
icity, the sensitivity of each tool at 0.99 specificity and
0.95 specificity are shown. The AROC value for each tool is
also given; these values are very similar, but not com-
pletely identical, to those given by the authors of the com-
munity binding resource; the small discrepancies are
likely due to the use of differing methods of calculating
the area under the ROC curve. Individual tool perform-
ance data for the HLA-B*3501 and H-2Kd peptides from
the community binding database, as well as for the HLA-
A*0201 peptides gathered from the literature, are shown
in Tables 2, 3, and 4, respectively.
Performance of the combined methods
The HBM and LDA were evaluated using ten-fold cross-
validation on the same four datasets (the HLA-A*0201,
HLA-B*3501, and H-2Kd datasets from the community
binding resource, and the HLA-A*0201 dataset from the
literature) as the individual tools.
The HBM requires that an individual tool specificity
parameter be chosen such that the tools' sensitivities at
that specificity can be used as the weights in equation 1.
The performance of the HBM was determined using indi-
vidual tool specificities of 0.99, 0.95, 0.90, and 0.80. In
general, it was found that using 0.99 individual tool spe-
cificity resulted in the best performance, while the use of
lower individual tool specificity parameters resulted in
somewhat weaker performance. Thus, all of the HBM per-
formance data described below were obtained using 0.99
individual tool specificity. Table 5 shows the performance
of the HBM on all four datasets.
For two of the three alleles, the HBM showed marked
improvements in sensitivity at high specificity compared
with the best-performing individual tools. The sensitivity
of the HBM at 0.99 specificity for HLA-A*0201 was 0.40,
a large increase over NetMHC ANN, whose sensitivity of
0.29 was the best among the individual tools. For HLA-
B*3501, the HBM sensitivity was 0.31 at a specificity of
0.99, while the highest sensitivity obtained by an individ-
ual tool was 0.24. The HBM showed similarly strong per-
formance when tested using the literature-derived HLA-
A*0201 data, achieving a sensitivity of 0.27, compared
with 0.19 for the best-performing individual tool. For H-
2Kd, however, the HBM was outperformed at 0.99 specif-
icity by the ARB matrix tool, which had a sensitivity of
0.50 versus 0.47 for the HBM. We note, however, that ARB
Matrix was trained using binders from the community
binding database, so its performance on the community
datasets is likely inflated [7]
At lower specificity thresholds, the advantage of the HBM
was only marginal. For instance, the sensitivity of the
HBM at 0.95 specificity for the HLA-A*0201 community
dataset was almost identical to that of the best individual
tool; for HLA-B*3501, the sensitivity of the HBM at spe-
cificity 0.95 was slightly worse than the individual tool
with the highest sensitivity at that specificity. Interest-
ingly, however, the HBM actually outperforms the indi-
vidual tools at specificity 0.95 for H-2Kd.
The linear discriminant scores displayed approximately
normal distributions, with moderate separation between
binders and non-binders. The distributions were closer to
normality for HLA-A*0201 dataset from the literature and
the H-2Kd datset, with more systematic deviations for the
other two datasets. While the nominal sensitivity and spe-
cificity of the LDA agreed reasonably well with the actual
and cross-validated values, we used the cross-validated
values for comparison purposes (Table 6). The distinction
between nominal and actual specificity is illustrated in
Figure 1.
LDA displayed an improvement over the individual tools
for the HLA-A*0201 community dataset, attaining a sen-
sitivity of 0.33 at 0.99 specificity – higher than that of all
the individual tools, but lower than that of the HBM. The
performance of the LDA on the other datasets was less
substantial. Its sensitivity on the HLA-A*3501 communtiy
data at 0.99 specificity was 0.21, compared to 0.24 for
ARB matrix and 0.31 for the HBM. However, we note
again that the ARB matrix sensitivity is probably inflated,
especially considering that the sensitivity for the second-
best tool at 0.99 specificity (NetMHC 2.0 Matrix) was
0.14. The performance of LDA on the H-2Kd dataset was
fairly strong, but still lower than that of both ARB Matrix
and the HBM. Finally, the performance of LDA on the lit-Immunome Research 2007, 3:5 http://www.immunome-research.com/content/3/1/5
Page 3 of 10
(page number not for citation purposes)
erature-derived HLA-A*0201 dataset was fairly weak at
both 0.99 specificity and 0.95 specificity.
Purely in terms of the AROC value, however, LDA outper-
forms the individual tools on all four datasets. This sug-
gests that while LDA provides strong "overall"
performance across the entire spectrum of specificities, it
achieves less improvement in the region of the ROC curve
that is of interest in this study – namely, the regions of
very high specificity.
Discussion
In this paper, results are given only for the three alleles
HLA-A*0201, HLA-B*3501, and H-2Kd. The approach
can be easily extended to any arbitrary MHC-I allele, pro-
vided that a sufficient number of tools make predictions
for that allele, and that there exists an adequate number of
known binding and non-binding peptides that can be
used to test the individual tools on that allele. The effects
of the latter conditions are born out in our results for H-
2Kd versus HLA-A*0201.
Table 2: Individual tool AROC values and sensitivity data for HLA-B*3501 using binders and nonbinders from the community binding 
resource.
Tool AROC 0.99 Specificity 0.95 Specificity
Rank Sensitivity Threshold Rank Sensitivity Threshold
ARB Matrix 0.849 1 0.242 12.890 1 0.422 296.090
Bimas 0.808 7 0.047 60.000 8 0.166 24.000
NetMHC 2.0 Matrix 0.789 2 0.137 32.386 2 0.336 28.404
HLA Ligand 0.786 8 0.043 162.000 4 0.237 145.000
Rankpep 0.769 5 0.071 124.000 3 0.256 107.000
Logistic Regression 0.764 11 0.024 0.655 11 0.123 0.259
SVMHC SYFPEITHI 0.742 3 0.118 0.680 6 0.204 0.420
SVMHC MHCPEP 0.733 8 0.043 1.560 6 0.204 1.140
MHCPred (position only) 0.692 6 0.057 140.600 9 0.156 210.860
MHCPred (interactions) 0.683 4 0.090 52.240 5 0.209 179.470
Predep 0.587 10 0.038 -6.020 10 0.128 -5.090
For details, see the caption for Table 1.
Table 1: Performances of the individual prediction tools on the HLA-A*0201 peptides from the community binding resource.
Tool AROC 0.99 Specificity 0.95 Specificity
Rank1 Sensitivity Threshold2 Rank Sensitivity Threshold
ARB Matrix 0.935 4 0.188 2.190 2 0.601 42.950
NetMHC 2.0 ANN 0.932 1 0.286 153.000 1 0.611 920.000
SMM 0.922 2 0.201 38.092 4 0.543 454.865
Bimas 0.920 3 0.198 324.068 3 0.552 47.991
SYFPEITHI 0.885 8 0.170 27.000 5 0.421 24.000
Multipred ANN 0.884 9 0.140 5.820 7 0.373 5.560
NetMHC 2.0 Matrix 0.872 6 0.177 24.329 10 0.358 20.129
SVMHC MHCPEP 0.870 12 0.115 1.000 11 0.334 0.520
Logistic Regression 0.862 13 0.101 0.364 9 0.364 0.108
SVMHC SYFPEITHI 0.854 7 0.176 0.950 8 0.367 0.490
HLA Ligand 0.825 10 0.137 141.000 14 0.274 127.000
Rankpep 0.822 15 0.077 103.000 13 0.306 83.000
MHCPred (Interactions) 0.818 5 0.182 43.350 6 0.377 99.080
MHCPred (position only) 0.814 11 0.116 21.330 12 0.311 65.310
Multipred HMM 0.798 14 0.090 7.530 15 0.244 7.090
Predep 0.788 16 0.045 -6.000 16 0.217 -5.130
The predictive performance of each tool for the HLA-A*0201 community binding data is shown using two measures: AROC score, and sensitivity 
when specificity is 0.99 and 0.95. 1Indicates how the sensitivity of each tool compares to that of the other tools at the indicated specificity; the tool 
with rank 1 has the highest sensitivity. 2The scoring threshold corresponding to the indicated specificity.Immunome Research 2007, 3:5 http://www.immunome-research.com/content/3/1/5
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We have used our HBM tool for the prediction of binders
from bench-lab experiments, with positive results. For
instance, in predicting binders for influenza virus in mice,
the best two 9-mers predicted by HBM turned out to gen-
erate the strongest responses in immunoassays [8].
Some comparative studies of binding prediction tools use
randomly-generated nonbinders. This study used known
nonbinders only. We contend that the use of known non-
binders contributes to a stronger practical assessment of
each tool's utility. Such nonbinders that might have been
selected by an experimenter for binding-affinity testing
due to the presence of good anchor residues. Randomly-
generated nonbinders tend to have anchor residues that
poorly match established motifs, and thus are typically
very easy to classify; in contrast, nonbinders reported in
the literature frequently have anchor residues that do con-
form to an established motif, making them more difficult
to classify. For a tool to be truly useful, it must be able to
differentiate between peptides that all have good anchor
residues, but whose non-anchor residues confer different
degrees of binding affinity.
Availability
The authors have elected not to make the HBM available
online, for two reasons: first, frequent server outages and
other problems with individual web-based tools often
prevent acquisition of all the requisite scores. Automatic
operation is therefore not possible. Second, the querying
of all the web-based tools can take a long time, making the
tool inconvenient for real-time web-based access. Inter-
ested researchers may, however, contact the authors
regarding obtaining the scripts implementing the HBM.
Conclusion
We have built a tool that heuristically combines the out-
put of several individual MHC-binding prediction tools,
and have shown that it achieves substantially improved
sensitivity at high specificity compared to the best individ-
ual tools, and is also superior to linear discriminant anal-
ysis at high specificity. This technique is very general, and
Table 4: Individual tool AROC values and sensitivity data for HLA-A*0201 using binders and nonbinders gathered from the literature
Tool AROC 0.99 Specificity 0.95 Specificity
Rank Sensitivity Threshold Rank Sensitivity Threshold
Multipred ANN 0.772 11 0.083 5.830 2 0.278 5.600
NetMHC 2.0 ANN 0.772 6 0.139 99.000 7 0.231 300.000
SYFPEITHI 0.762 1 0.194 27.000 2 0.278 25.000
SVMHC MHCPEP 0.745 1 0.194 0.910 4 0.269 0.740
Logistic Regression 0.743 10 0.093 0.424 12 0.167 0.281
ARB Matrix 0.742 8 0.102 1.860 14 0.139 3.550
Bimas 0.722 12 0.074 437.482 9 0.213 159.970
NetMHC 2.0 Matrix 0.719 14 0.046 27.193 10 0.194 23.585
SMM 0.716 4 0.157 100.484 6 0.250 262.434
Rankpep 0.708 3 0.176 89.000 5 0.259 83.000
MHCPred (interactions) 0.707 6 0.139 61.660 1 0.287 100.690
SVMHC SYFPEITHI 0.706 5 0.148 0.970 11 0.185 0.820
HLA Ligand 0.705 12 0.074 147.000 12 0.167 138.000
MHCPred (position only) 0.700 8 0.102 28.250 7 0.231 67.300
Multipred HMM 0.695 16 0.009 7.570 15 0.102 7.290
Predep 0.627 15 0.019 -6.450 16 0.093 -5.330
For details, see the caption for Table 1. The peptides in this literature-derived dataset are available in Additional File 1.
Table 3: Individual tool AROC values and sensitivity data for H-2Kd using binders and nonbinders from the community binding resource.
Tool AROC 0.99 Specificity 0.95 Specificity
Rank Sensitivity Threshold Rank Sensitivity Threshold
SYFPEITHI 0.918 3 0.300 27.000 4 0.483 25.000
ARB Matrix 0.899 1 0.500 15.470 1 0.583 40.800
Bimas 0.888 4 0.183 4800.000 3 0.533 2880.000
Rankpep 0.886 2 0.317 107.000 2 0.567 98.000
For details, see the caption for Table 1.Immunome Research 2007, 3:5 http://www.immunome-research.com/content/3/1/5
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can be updated as new prediction tools become available.
Given this, the HBM should be extremely valuable for
researchers wishing to scan large proteomes for potential
epitopes. Additionally, the combination of the tools using
linear discriminant analysis consistently displays
improved overall operating characteristics (as measured
by the AROC value) over the individual tools, and thus
would be useful for researchers desiring to identify a large
number of the potential binders in a smaller dataset, such
as a single protein.
The success of our heuristic-based tool substantiates the
hypothesis that peptides predicted by a number of tools is
more likely to bind than those predicted by just one tool,
and that the likelihood of a particular peptide being a
binder is related to the number of tools that predict it, as
well as the accuracy of those tools. In the same vein, our
data suggests that the performance of the heuristic-based
approach improves when more individual prediction
tools are available. The fact that combining the output of
several tools results in increased performance indicates
that, as of now, no single tool is able to extract all the
information inherent in the data currently available. Thus,
continued work on improved MHC-binding prediction is
necessary.
Methods
Determination of prediction tools
We have identified a total of 16 different prediction tools
from 12 different research groups. Where there are two
tools from the same group, they differ either in the
method used to predict binding affinity or in the data
used to train the model. The tools tested are as follows:
Bimas [9], Rankpep [10], SYFPEITHI [11], NetMHC 2.0
ANN and NetMHC 2.0 Matrix [5,12,13], SVMHC SYF-
PEITHI and SVMHC MHCPEP [14], HLA Ligand [15], Pre-
dep [16], SMM [2], MHCPred (position only) and
MHCPred (interactions) [17,18], Multipred HMM and
Multipred ANN [19-21], ARB Matrix [7], and a locally
implemented logistic regression-based tool [22].
Creating a collection of peptides for evaluating the 
predictive performance of each tool
Prediction of peptide binding was evaluated for three dif-
ferent alleles: HLA-A*0201, HLA-B*3501, and H-2Kd.
These alleles differ substantially in the number of availa-
ble tools that make predictions for them: all of the afore-
mentioned tools predict for HLA-A*0201, eleven make
predictions for HLA-B*3501, and just four predict for H-
2Kd. Thus, these alleles were chosen so that the perform-
ance of our combined tool (HBM) and linear discriminate
analysis (LDA) could be evaluated when different num-
bers of individual tools are employed.
Two sources of data were used for comparative analysis of
prediction tools in this study. The first was the community
binding resource [6], a large, recently published database
containing experimentally determined affinity values for
the binding of peptides to many different MHC-I alleles.
This dataset of testing peptides could potentially be
expanded further by incorporating peptides from such
online databases as SYFPEITHI [11], MHCPEP [23], HLA
Ligand [15], and EPIMHC [24]. However, the use of the
latter online databases presents a problem for the current
study. As the models underlying many existing prediction
tools were trained using data from these latter databases,
the subsequent testing of the individual tools with these
same peptides may result in an inaccurate estimation of
each tool's predictive performance. For instance, tool A
may be judged better than tool B merely because tool A
was trained using the same peptides with which it was
tested, while tool B was not. As combining the scores of
Table 5: Performance of the heuristic-based method on all four datasets
Specificity HLA-A*0201 (comm) HLA-B*3501 (comm) H-2Kd (comm) HLA-A*0201 (lit)
0.99 0.404 0.313 0.467 0.271
0.95 0.618 0.393 0.617 0.475
The sensitivity of the HBM is shown at 0.99 specificity and 0.95 specificity for all four of the datasets used in this study. All values were obtained 
using a value of 0.99 for the individual tool specificity parameter. The abbreviation "comm" refers to peptides derived from the community binding 
database, while "lit" refers to peptides gathered from the literature.
Table 6: Performance of linear discriminant analysis on all four datasets
Specificity HLA-A*0201 (comm) HLA-B*3501 (comm) H-2Kd (comm) HLA-A*0201 (lit)
0.99 0.324 0.213 0.417 0.102
0.95 0.718 0.436 0.633 0.333
AROC 0.956 0.885 0.935 0.828
The sensitivity of the combined tool is shown at 0.99 specificity and 0.95 specificity for all four of the datasets used in this study. The abbreviation 
"comm" refers to peptides derived from the community binding database, while "lit" refers to peptides gathered from the literature.Immunome Research 2007, 3:5 http://www.immunome-research.com/content/3/1/5
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Q-Q plot showing distribution of LDA scores for the HLA-A*0201 community data set Figure 1
Q-Q plot showing distribution of LDA scores for the HLA-A*0201 community data set. The horizontal axis has 
been scaled according to normal probabilities, so that points from a normally distributed variable would fall along a straight line 
(shown in blue). Scores lying above a threshold indicated by a horizontal line would be classified as epitopes. A level exceeding 
99% of a normal distribution defines a nominal specificity of 0.99, whereas an actual specificity of 0.99 requires a threshold 
meeting the actual distribution of points at the 0.99 vertical line. The realized sensitivity of 0.32 for a specificity of 0.99 is indi-
cated as the proportion of epitopes whose scores lie above the threshold of 0.95.
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the individual tools relies on an accurate appraisal of the
performance of each tool, it is necessary to avoid the use
of peptides with which the individual tools have been
trained. Thus, we used only the community binding
resource as our source of binding-affinity data. Only pep-
tides of length 9 were considered, because all tools make
predictions for peptides of this length. Peptides with IC50
< 500 nM were classified as binders, while those having
IC50 > 500 nM were classified as nonbinders. In total,
there were 1184 binders and 1905 non-binders to HLA-
A*0201, 211 binders and 525 nonbinders to HLA-
A*3501, and 60 binders and 116 nonbinders to H-2Kd.
For comparison purposes, the tools were also tested using
an independent dataset consisting of peptides gathered
only from published literature [25-33]. Again, only non-
amers were chosen. Classifying a given peptide as a binder
or a nonbinder was performed as follows: if IC50 values
were reported (as in the community binding database and
most literature sources), then the standard binding
threshold of 500 nM was used; where some other type of
assay was done to determine binding affinity, the classifi-
cation given by the authors was used. In the latter case, if
no classification was given by the authors, the peptides
were not used. Finally, to avoid bias in the data, peptides
were filtered such that where two peptides differed at
fewer than two residues, one peptide was randomly
removed. The resultant dataset consisted of 108 binders
and 108 nonbinders to HLA-A*0201, and are given in
Additional File 1. Due to scarcity of published data, it was
not possible to construct similar datasets for HLA-B*3501
or H-2Kd.
Performance measures
Binding prediction programs give a numeric score to each
considered peptide. Each score can be converted to a
binary prediction by comparing against a tool-specific
threshold – if the score is greater or equal, then the pep-
tide is a predicted binder; otherwise, it is a predicted non-
binder.
Sensitivity is the proportion of experimentally determined
binders that are predicted as binders and is defined as true
positives/(true positives + false negatives). Specificity is the
proportion of experimentally determined nonbinders
that are predicted as nonbinders, and is defined as true
negatives/(true negatives + false positives). The traditional
way to measure the performance of a classifier is to use a
receiver operating characteristic (ROC) curve. However,
ROC curves do not always give a good measure of practi-
cal utility. For a researcher scanning a large proteome for
potential epitopes, specificity may be much more impor-
tant than sensitivity. Imagine scanning a proteome con-
sisting of 10,000 overlapping nonamers, 50 of which
(unbeknownst to the experimenter) are good binders to
the MHC-I allele of interest. Consider further that predic-
tion tool A has 0.70 sensitivity at 0.80 specificity and 0.05
sensitivity at 0.99 specificity.
Tool B has 0.50 sensitivity at 0.80 specificity and 0.20 sen-
sitivity at 0.99 specificity. While tools A and B might have
the same area under the ROC curve (AROC), tool A is supe-
rior at 0.80 specificity and tool B is superior at 0.99 specif-
icity. If tool A is used at a threshold corresponding to 0.80
specificity, then approximately 2000 peptides must be
tested in order to find 35 of the high-affinity binders. In
contrast, if tool B is used at a threshold corresponding to
0.99 specificity, only about 100 peptides would have to be
tested in order to find 10 of the high-affinity binders. Due
to the high cost of experimental testing, and because
knowledge of all the binders in a given proteome is usu-
ally not needed, the latter scenario would be preferable.
We therefore conclude that good sensitivity at very high
specificity is a more practical measure of a tool's useful-
ness than the AROC value, and have thus used sensitivity at
high values of specificity as the primary assessor of the
practical utility of each tool. For completeness, however,
we also include each tool's AROC value.
Combining the scores of the individual tools
We propose a heuristic-based method (HBM) for combin-
ing scores from individual prediction tools to make a bet-
ter prediction. This method takes advantage of the
observation that most of the individual tools make very
few false positive predictions when the classification
threshold is set sufficiently high, but correspondingly
make few predictions of positives. If the tools identify dif-
ferent actual binders, combining such predictions may
result in a greater number of rrue positives. The method
also tries to take advantage of the "collective wisdom" of
a group of predictive tools. The individual tools are based
on a variety of techniques. Instead of trying to find the
"best" technique, we try to combine the best that each
technique has to offer. This is an extension of the idea
used by prediction tools such as MULTIPRED [19] which
combine predictions made by a few methods.
Our proposed combined prediction tool ("HBM") takes a
protein sequence as input, queries all of the individual
prediction tools getting from each the predicted binding
affinity for all nonamers in the protein, computes a com-
bined score for each nonamer, and finally predicts binders
based on the combined scores for all nonamers. The tool
is implemented as a Perl script.
The first step in our HBM is to select a specificity for the
individual tools. Each tool is then weighted according to
its sensitivity at that specificity. Next, the score given to
each peptide by a given prediction tool is compared to the
tool-specific threshold value for that specificity. If theImmunome Research 2007, 3:5 http://www.immunome-research.com/content/3/1/5
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score is better than or equal to the threshold score, then
that tool predicts the peptide as a binder, and the weight
(sensitivity at the chosen specificity) for that tool is added
to the total score for the peptide. Otherwise, the peptide's
total score remains unchanged. For peptide x and each
prediction tool t, we have
where Bt(x) is 1 if peptide x is predicted to bind by tool t
and 0 otherwise, and Wt is the weight of tool t. Combined-
Score(x) is then compared to a threshold in order to clas-
sify  x  as either a predicted binder or a predicted
nonbinder.
The performance of the HBM was determined using 10-
fold cross-validation: in each fold, 90% of the peptides
(the "training peptides") were used to determine the per-
formances of the individual tools, and these performance
data were used by the HBM as described above to make
predictions for the remaining 10% (the "testing pep-
tides"). Each peptide was used as a testing peptide exactly
once. The scores given to each testing peptide were then
used to calculate specificity and sensitivity values for the
HBM in the same manner as was described for the individ-
ual tools. To minimize experimental error due to the ran-
dom partitioning of the peptides into training and testing
sets, the entire process described above was repeated ten
times, and the HBM sensitivity at each specificity was
taken to be the average of its sensitivity in the ten trials.
While AROC values are shown for the individual tools and
for the LDA, no such values could be computed for the
HBM. The reason for this is that, at high individual tool
specificity parameters, most nonbinding peptides get an
HBM score of zero, and therefore the ROC curve contains
no points for specificities between 0 and approximately
0.85–0.90.
Comparison technique
A standard method for combining variables to distinguish
two categories is linear discriminant analysis (LDA) [34].
If y is the vector of scores from all the tools for a particular
peptide, it is classified according to the value of the linear
discriminant
(μ1 - μ0)'∑-1y,
where μ0 and μ1 are the vectors of means for non-epitopes
and epitopes, respectively, and ∑ is the average covariance
matrix of the scores within the two groups. This method is
optimal (in the sense of minimizing the probability of
misclassification) if the scores have a multivariate normal
distribution with the same covariance matrix for epitopes
and non-epitopes. More sophisticated methods have been
developed without the normality assumption, but doubts
have been expressed about their advantage [35]. The sep-
aration between the groups can then be quantified by
δ2 = (μ1 - μ0)'∑-1(μ1 - μ0).
Under the normality assumption, if the specificity is fixed
at 1 - α, then the sensitivity will be
Φ (δ + Φ-1(α)),
where Φ is the cumulative distribution function (cdf) of
the standard normal distribution. AROC can be calculated
as Φ (δ/ ). The threshold for classification is deter-
mined by the prior probability p1 that a peptide is an
epitope, which is related to the specificity by
p1 = [1 + exp (-δ2/2 - δΦ-1(α))]-1.
A number of the tools displayed notably non-normal dis-
tributions. Most of these were highly skewed, but became
close to normal when transformed to logarithms. The
scores of three tools (NetMHC 2.0 ANN, Multipred ANN,
and the logistic regression-based tool) had sigmoidal dis-
tributions. These became approximately normal when
converted to scaled logits. A "logit" is a transformation of
a probability p (between 0 and 1) to log(p/(1 - p)). For a
variable y which is restricted between a and b, a "scaled
logit" can be calculated via log((y - a + ε)/(b - y - δ)), where
ε and δ are small adjustments to avoid zeros. ε = (y- - a)/2
and δ = (b - y+)/2, y- and y+ being the smallest and largest
observed values greater or less than a or b, respectively.
The actual performance of the linear discriminant on the
transformed scores was estimated using ten-fold cross-val-
idation. Computations were done using S-PLUS version
7.0.0. Figures were created with MATLAB 7.
Except for the H-2Kd dataset, the cross-validated specifici-
ties fell short of the nominal ones. To realize specificities
of 0.99 and 0.90, the threshold was adjusted to a nominal
specificity such that the cross-validated values were as
close as possible to the target values. Figure 1 shows the
distributions of the LDA scores for the community HLA-
A*0201 data set. The diagonal lines indicate where the
points are expected to fall for perfectly normal data. A spe-
cificity of 0.99 corresponds to a horizontal line such that
99% of the non-epitopes fall below this line. Because of
the slight upward curvature of the non-epitope distribu-
tion, a nominal specificity of 0.99 falls short of this goal,
but the larger nominal value of 0.9975 gives the correct
threshold. About 32% of the epitopes give LDA scores
above this value. Distributions of LDA scores for the the
other datasets are given in Additional Files 2, 3 and 4.
CombinedScore( ) ( ) xB x W tt
t
= () ∑ 1
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